◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Crinetics Pharmaceuticals Inc (CRNX) EBITDA 2016–TTM

Name: Crinetics Pharmaceuticals Inc (CRNX) ebitda history 2016-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-08-16

Crinetics Pharmaceuticals Inc annual ebitda for fiscal 2025 was -$461 million, a decrease of 55.7% from -$296 million in fiscal 2024. All figures are reported results from public filings — no estimates or projections.

CRNX Annual EBITDA

EBITDA (annual)	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
EBITDA	—	($461M)	($296M)	($213M)	($167M)	($107M)	($74M)	($53M)	($28M)	($9M)	($6M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CRNX Quarterly EBITDA

EBITDA (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
EBITDA	—	($127M)	($122M)	($129M)	($115M)	($96M)	($80M)	($76M)	($73M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EBITDA at Comparable Companies

KRYS EBITDA — Krystal Biotech Inc
KYMR EBITDA — Kymera Therapeutics Inc
IONS EBITDA — Ionis Pharmaceuticals Inc
SYRE EBITDA — Spyre Therapeutics Inc.
PCVX EBITDA — Vaxcyte Inc
IMVT EBITDA — Immunovant Inc

More CRNX metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow · Shares Outstanding

All CRNX financial statements → Interactive CRNX charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.